During a global pandemic, the pharmaceutical industry must juggle the need for speed and the need to protect patient safety. A strong regulatory strategy makes it possible to accelerate drug development without getting slowed down by compliance considerations.
The science of viral vector manufacturing is generating a lot of excitement, and companies in this space are under pressure to move fast and make cost-effective decisions; this can occasionally result in speed at the expense of due diligence.
Multimodal manufacturing optimizes product combinations based on manufacturing and regulatory similarity and compatibility. Manufacturers must produce a variety of Advanced Therapy Medicinal Products (ATMPs) quickly and efficiently. Why not design a multi-modal ATMP facility?
All eyes are on those on the front lines seeking to develop and produce new drugs. There’s unprecedented pressure to offer both immediate treatments for those affected and long-term biotherapies and vaccines to prevent future epidemics.